ResMed Inc (ASX: RMD) Share Price and News
Price
$38.23
Movement
0.28 (-0.73%)
as at 6 Jun - Closed (20 mins delayed)
52 Week Range
$27.13 - $40.75
1 Year Return
+20.3%
ResMed Inc Chart and Price Data
2025
2025
2025
2025
$30
$40
$50
$30
$40
$50
$30
$40
$50
$30
$40
$50
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$56.03 billion
P/E Ratio
27.85
Dividend Yield
0.86%
Shares Outstanding
1.47 billion
Earnings per share
0.891
Dividend per share
0.33
Year To Date Return
4.42%
Earnings Yield
3.59%
Franking
-
Share Price
$38.23
Day Change
0.28 (-0.73%)
52 Week Range
$27.13 - $40.75
Yesterday's Close
$38.51
Today's Open
$38.50
Days Range
$38.20 - $38.62
Volume
644,929
Avg. Volume (1 month)
757,665
Turnover
$24,746,966
as at 6 Jun - Closed
ResMed Inc (ASX: RMD)
Latest News
How to invest
How to turn the ASX into a passive income machine
How to invest
How ASX shares can help you retire early
Growth Shares
Top brokers name 3 top ASX growth shares to buy now
Healthcare Shares
Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?
Blue Chip Shares
3 high-conviction ASX 200 shares I'd buy in June
Broker Notes
Where to invest $10,000 in ASX 200 shares this month
How to invest
How ASX 200 stocks and ASX ETFs can be combined to build the perfect portfolio
How to invest
How to generate $52,000 of passive income from ASX shares
How to invest
How I profited from the last share market crash (and what I could do better next time)
How to invest
How $250 a month in ASX shares could turn into $500,000
Growth Shares
The ultimate ASX growth shares to buy with $5,000
Growth Shares
Where to invest $1,000 into ASX shares in June
Frequently Asked Questions
-
Yes. As well as being listed on the ASX since November 1999, ResMed trades on the New York Stock Exchange under the ticker code NYSE: RMD.
-
Yes, historically ResMed pays unfranked quarterly dividends each year. It does not offer a dividend reinvestment plan.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 07 May 2025 | $0.0581 | 0.00% | Interim | 12 Jun 2025 |
| 12 Feb 2025 | $0.0581 | 0.00% | Interim | 20 Mar 2025 |
| 06 Nov 2024 | $0.0555 | 0.00% | Interim | 12 Dec 2024 |
| 14 Aug 2024 | $0.0561 | 0.00% | Final | 19 Sep 2024 |
| 08 May 2024 | $0.0508 | 0.00% | Interim | 13 Jun 2024 |
| 07 Feb 2024 | $0.0517 | 0.00% | Interim | 14 Mar 2024 |
| 08 Nov 2023 | $0.0528 | 0.00% | Interim | 14 Dec 2023 |
| 16 Aug 2023 | $0.0524 | 0.00% | Final | 21 Sep 2023 |
| 10 May 2023 | $0.0460 | 0.00% | Interim | 15 Jun 2023 |
| 08 Feb 2023 | $0.0444 | 0.00% | Interim | 16 Mar 2023 |
| 09 Nov 2022 | $0.0466 | 0.00% | Interim | 15 Dec 2022 |
| 17 Aug 2022 | $0.0445 | 0.00% | Final | 22 Sep 2022 |
| 11 May 2022 | $0.0429 | 0.00% | Interim | 16 Jun 2022 |
| 09 Feb 2022 | $0.0410 | 0.00% | Interim | 17 Mar 2022 |
| 10 Nov 2021 | $0.0403 | 0.00% | Interim | 16 Dec 2021 |
| 18 Aug 2021 | $0.0412 | 0.00% | Final | 23 Sep 2021 |
| 12 May 2021 | $0.0354 | 0.00% | Interim | 17 Jun 2021 |
| 10 Feb 2021 | $0.0352 | 0.00% | Interim | 18 Mar 2021 |
| 11 Nov 2020 | $0.0378 | 0.00% | Interim | 17 Dec 2020 |
| 19 Aug 2020 | $0.0379 | 0.00% | Final | 24 Sep 2020 |
| 13 May 2020 | $0.0423 | 0.00% | Interim | 18 Jun 2020 |
| 12 Feb 2020 | $0.0406 | 0.00% | Interim | 19 Mar 2020 |
| 06 Nov 2019 | $0.0396 | 0.00% | Interim | 12 Dec 2019 |
| 14 Aug 2019 | $0.0403 | 0.00% | Final | 19 Sep 2019 |
| 08 May 2019 | $0.0371 | 0.00% | Interim | 13 Jun 2019 |
| 06 Feb 2019 | $0.0365 | 0.00% | Interim | 14 Mar 2019 |
| 07 Nov 2018 | $0.0356 | 0.00% | Interim | 13 Dec 2018 |
| 15 Aug 2018 | $0.0357 | 0.00% | Final | 20 Sep 2018 |
| 09 May 2018 | $0.0326 | 0.00% | Interim | 14 Jun 2018 |
| 07 Feb 2018 | $0.0315 | 0.00% | Interim | 15 Mar 2018 |
| 08 Nov 2017 | $0.0320 | 0.00% | Interim | 14 Dec 2017 |
| 16 Aug 2017 | $0.0308 | 0.00% | Final | 21 Sep 2017 |
| 10 May 2017 | $0.0313 | 0.00% | Interim | 15 Jun 2017 |
| 08 Feb 2017 | $0.0303 | 0.00% | Interim | 16 Mar 2017 |
| 09 Nov 2016 | $0.0303 | 0.00% | Interim | 15 Dec 2016 |
| 17 Aug 2016 | $0.0300 | 0.00% | Final | 22 Sep 2016 |
| 18 May 2016 | $0.0291 | 0.00% | Interim | 16 Jun 2016 |
| 09 Feb 2016 | $0.0295 | 0.00% | Interim | 17 Mar 2016 |
| 17 Nov 2015 | $0.0292 | 0.00% | Interim | 17 Dec 2015 |
RMD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| 6th Jun 2025 2025-06-06T08:21:05 | Notice of Proposed Sale of Securities | YesNo | 8:21am | 3 | 141k |
| 4th Jun 2025 2025-06-04T10:00:54 | Statement of CDIs on issue - RMD | YesNo | 10:00am | 3 | 11k |
| 4th Jun 2025 2025-06-04T08:27:28 | Statement of Changes in Beneficial Ownership | YesNo | 8:27am | 2 | 12k |
| 4th Jun 2025 2025-06-04T08:26:43 | Statement of Changes in Beneficial Ownership | YesNo | 8:26am | 2 | 11k |
| 4th Jun 2025 2025-06-04T08:22:38 | Notice of Proposed Sale of Securities | YesNo | 8:22am | 3 | 137k |
| 4th Jun 2025 2025-06-04T08:22:33 | Notice of Proposed Sale of Securities | YesNo | 8:22am | 3 | 141k |
| 30th May 2025 2025-05-30T08:21:13 | FORM SD | YesNo | 8:21am | 7 | 245k |
| 28th May 2025 2025-05-28T08:17:56 | Statement of Changes in Beneficial Ownership | YesNo | 8:17am | 2 | 11k |
| 23rd May 2025 2025-05-23T08:19:38 | Notice of Proposed Sale of Securities | YesNo | 8:19am | 3 | 543k |
| 23rd May 2025 2025-05-23T08:19:33 | Statement of Changes in Beneficial Ownership | YesNo | 8:19am | 2 | 625k |
About ResMed Inc
ResMed Inc (ASX: RMD) is a global leader in sleep technology. It develops, manufactures, and distributes medical devices – such as flow generators, CPAP masks, and accessories – and cloud-based software applications that diagnose, treat, and manage a range of respiratory disorders including sleep apnea, chronic obstructive pulmonary disease (COPD), and neuromuscular disease.
It also provides software platforms to support professionals and caregivers to help patients in an out-of-hospital setting. The company operates in more than 140 countries, with manufacturing facilities in Australia, Singapore, France, and the United States. ResMed was established in Australia in 1989 but is now based in San Diego in the United States.
RMD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 06 Jun 2025 | $38.23 | $-0.28 | -0.73% | 644,929 | $38.50 | $38.62 | $38.20 |
| 05 Jun 2025 | $38.51 | $0.18 | 0.47% | 614,840 | $38.45 | $38.66 | $38.43 |
| 04 Jun 2025 | $38.33 | $0.40 | 1.05% | 572,326 | $38.36 | $38.45 | $38.23 |
| 03 Jun 2025 | $37.93 | $0.23 | 0.61% | 419,806 | $37.69 | $37.95 | $37.46 |
| 02 Jun 2025 | $37.70 | $-0.22 | -0.58% | 616,381 | $37.76 | $37.94 | $37.42 |
| 30 May 2025 | $37.92 | $-0.32 | -0.84% | 648,482 | $37.78 | $38.15 | $37.76 |
| 29 May 2025 | $38.24 | $0.03 | 0.08% | 423,051 | $38.26 | $38.39 | $38.15 |
| 28 May 2025 | $38.21 | $0.08 | 0.21% | 430,783 | $38.40 | $38.45 | $38.06 |
| 27 May 2025 | $38.13 | $0.74 | 1.98% | 653,788 | $37.69 | $38.13 | $37.43 |
| 26 May 2025 | $37.39 | $-0.91 | -2.38% | 415,675 | $37.46 | $37.50 | $37.21 |
| 23 May 2025 | $38.30 | $0.06 | 0.16% | 507,440 | $38.35 | $38.47 | $38.21 |
| 22 May 2025 | $38.24 | $-0.41 | -1.06% | 669,926 | $38.00 | $38.45 | $38.00 |
| 21 May 2025 | $38.65 | $1.49 | 4.01% | 1,518,328 | $38.62 | $38.97 | $38.52 |
| 20 May 2025 | $37.16 | $-1.71 | -4.40% | 2,603,844 | $38.05 | $38.09 | $36.02 |
| 19 May 2025 | $38.87 | $-0.12 | -0.31% | 589,178 | $38.85 | $39.04 | $38.70 |
| 16 May 2025 | $38.99 | $0.63 | 1.64% | 702,374 | $38.82 | $39.07 | $38.80 |
| 15 May 2025 | $38.36 | $0.07 | 0.18% | 847,120 | $38.29 | $38.48 | $38.03 |
| 14 May 2025 | $38.29 | $0.01 | 0.03% | 1,387,079 | $38.31 | $38.47 | $38.17 |
| 13 May 2025 | $38.28 | $0.17 | 0.45% | 901,683 | $38.98 | $38.98 | $38.28 |
| 12 May 2025 | $38.11 | $-0.08 | -0.21% | 388,889 | $38.26 | $38.50 | $38.04 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 02 Jul 2024 | Christopher Roberts | Issued | 12,000 | $611,400 |
Issue of options. https://www.aspecthuntley.com.au/asxdata/20040709/pdf/00445695.pdf, usd$
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Peter Craig Farrell | Non-Executive DirectorNon-Executive Chairman | Jul 2002 |
No profile reported in Annual Report.
|
| Mr Ronald R Taylor | Non-Executive Director | Jan 2005 |
Mr Taylor is a director of Actavis, Inc. and Red Lion Hotels Corp. From 2002 until his appointment to the ResMed board in 2005, he served as chairman of the ResMed Foundation. In 1987, Mr. Taylor founded Pyxis Corporation where he served as chairman, president, and chief executive officer until its purchase by Cardinal Health, Inc., in 1996.
|
| Mr Richard Sulpizio | Non-Executive Director | Aug 2005 |
Mr Sulpizio has served as president and chief executive officer of Qualcomm Enterprise Services. He currently serves as a senior advisor to Qualcomm Enterprise Services. Mr Sulpizio held various positions with Qualcomm during his 20-year tenure there, including president and chief operating officer. He served as a member of Qualcomm's board of directors from 2000 until 2007.
|
| Mr Michael J Farrell | Chief Executive OfficerExecutive Director | Mar 2013 |
Mr Farrell was foundation director of Biomedical Engineering at the University of New South Wales where he currently serves as a visiting professor and as chairman of the UNSW Centre for Innovation and Entrepreneurship. Since 2005, Dr Farrell has been a director of NuVasive, Inc. He also serves as the non-executive chair of QRxPharma.
|
| Ms Carol Burt | Non-Executive Director | Aug 2014 |
No profile reported in Annual Report.
|
| Ms Karen Ruth Drexler | Non-Executive Director | Nov 2017 |
No profile reported in Annual Report.
|
| Mr Jan De Witte | Non-Executive Director | May 2019 |
Mr De Witte is the chief executive officer and member of the board of directors of Barco NV.
|
| Ms Harjit Gill | Non-Executive Director | Nov 2018 |
No profile reported in Annual Report.
|
| Mr John Hernandez | Non-Executive Director | Nov 2021 |
No profile reported in Annual Report.
|
| Mr Desney Tan | Non-Executive Director | Nov 2021 |
No profile reported in Annual Report.
|
| Mr Christopher DelOrefice | Non-Executive Director | Aug 2024 |
Mr DelOrefice, is the executive vice president and chief financial officer of Becton Dickinson and Company and has served in that role since September 2021. Previously, he served as Vice President, Investor Relations at Johnson & Johnson from August 2018 to September 2021 and Chief Financial Officer of North America Hospital Medical Devices, Johnson & Johnson from June 2017 to August 2018.
|
| Brett A. Sandercock | Chief Financial Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| N/A | 0 | 0.00% |